APRIL Inhibitors
1 drugsAbout APRIL
APRIL, or A Proliferation-Inducing Ligand, is a protein involved in cell growth and survival. It is considered a target of interest for drug development due to its role in cellular processes.
Currently, there is no genetic evidence available linking APRIL to specific diseases. However, the existence of an approved drug suggests that modulating APRIL activity can have therapeutic benefits.
There is one FDA-approved drug, VOYXACT, targeting APRIL, developed by OTSUKA PHARM CO LTD. VOYXACT is a biologic (other) and falls into the 'Other' therapeutic area.
Top APRIL Drugs
The competitive landscape is currently limited to OTSUKA PHARM CO LTD.
Low competition suggests a potential first-mover advantage for new entrants.
APRIL Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets APRIL, using biologic (other) modality.
The lack of modality diversity indicates a whitespace opportunity for small molecules or antibodies.
APRIL Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on APRIL. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 0 | 0 | 4 | - |
| Phase 3 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
APRIL Drug Approval Timeline (2025 - 2025)
The first and most recent drug approval for APRIL was VOYXACT in 2025.
Recent approval suggests growing interest, but further approvals are needed to confirm trajectory.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on APRIL. A trial counts if an approved drug acting on APRIL is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.